<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983122</url>
  </required_header>
  <id_info>
    <org_study_id>BakirkoySKGeneralSurgery</org_study_id>
    <nct_id>NCT03983122</nct_id>
  </id_info>
  <brief_title>Outcomes of Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Long Term Outcomes of Laparoscopic Sleeve Gastrectomy: First Five Years' Results of a Single Center From a Developing Country</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bakirkoy Dr. Sadi Konuk Research and Training Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bakirkoy Dr. Sadi Konuk Research and Training Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess 5 year long-term outcomes of laparoscopic sleeve
      gastrectomy emphasizing weight loss and modification of comorbidities such as type 2 diabetes
      mellitus, hypertension and gastroesophageal reflux disease from a developing country, Turkey.
      Prospectively-collected patient data will retrospectively reviewed. To measure the efficacy
      of the procedure, we will calculate the excess weight loss percentage (EWL %). Effective
      weight loss after LSG will accepted as more than 50%. The changes in the status of the type 2
      diabetes mellitus, hypertension, gastroesophageal reflux disease will be observed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2012</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>5 years</time_frame>
    <description>Weight loss after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remision of comorbid diseases</measure>
    <time_frame>5 years</time_frame>
    <description>The pharmacological treatment status of comorbidities related to obesity of type 2 diabetes (T2DM) and hypertension and gastroesophageal reflux will be observed with questions about &quot;did it stop after surgery (improvement), did the dose or number of medications used reduce (resolution), or were there no changes?&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Laparoscopic Sleeve Gastrectomy</condition>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergo laparoscopic sleeve gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic sleeve gastrectomy</intervention_name>
    <description>Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria were, patients between 18 to 65 years old, initial body mass index
             (BMI) 40 kg/m2 or BMI of 35 kg/m2 in the presence of additional comorbidity and
             failure of conservative treatment for 2 years.

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bakirkoy Dr. Sadi Konuk Research and Training Hospital</investigator_affiliation>
    <investigator_full_name>Hakan Seyit</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

